Perspective Therapeutics Stock (AMEX: CATX)

Dernières nouvelles pour Perspective Therapeutics (AMEX:CATX) Stock

PERSPECTIVE THERAPEUTICS INC

Perspective Therapeutics

Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.

Costamare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMRE#NYSE">CMRE</a>) reported quarterly earnings of $0.77 per share which beat the analyst consensus estimate of $0.67 by 14.93 percent. This is a 1.32 percent increase over earnings of $0.76 per share from the same period last year. The company reported quarterly sales of $210.898 million which beat the analyst consensus estimate of $210.000 million by 0.43 percent. This is a 0.41 percent decrease over sales of $211.767 million the same period last year.

Earnings

Earnings Beats

News

CMRE

Costamare Q2 Adj. EPS $0.77 Beats $0.67 Estimate, Sales $210.898M Beat $210.000M Estimate

WIIM

Cigna Group shares are trading higher after the company reported better-than-expected Q2 adjusted EPS and sales.

CVS Health shares are trading higher after the company reported better-than-expected Q2 adjusted EPS and sales.

Telsey Advisory Group analyst Joseph Feldman maintains Holley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLLY#NYSE">HLLY</a>) with a Outperform and maintains $2.75 price target.

Price Target

Analyst Ratings

HLLY

Telsey Advisory Group Maintains Outperform on Holley, Maintains $2.75 Price Target

Needham analyst Kyle Peterson maintains Axos Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AX#NYSE">AX</a>) with a Buy and raises the price target from $92 to $102.

Needham Maintains Buy on Axos Financial, Raises Price Target to $102

Teleflex shares are trading higher after the company raised its FY2025 adjusted EPS and sales guidance above estimates.

SNDL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.06) by 116.67 percent. This is a 150 percent increase over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $244.769 million which beat the analyst consensus estimate of $231.500 million by 5.73 percent. This is a 7.30 percent increase over sales of $228.127 million the same period last year.

SNDL

SNDL Q2 EPS $0.01 Beats $(0.06) Estimate, Sales $244.769M Beat $231.500M Estimate

BorgWarner shares are trading higher after the company raised its FY2025 adjusted EPS and sales guidance above estimates.

Exelon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXC#NASDAQ">EXC</a>) affirms FY2025 Adj EPS guidance from $2.64-$2.74 to $2.64-$2.74 vs $2.69 analyst estimate..

Guidance

Exelon Affirms FY2025 Adj EPS Guidance of $2.64-$2.74 vs $2.69 Est

Kimco Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KIM#NYSE">KIM</a>) raises FY2025 FFO guidance from $1.71-$1.74 to $1.73-$1.75 vs $1.73 analyst estimate..

Kimco Realty Raises FY2025 FFO Guidance from $1.71-$1.74 to $1.73-$1.75 vs $1.73 Est

Exelon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXC#NASDAQ">EXC</a>) reported quarterly earnings of $0.39 per share which missed the analyst consensus estimate of $0.44 by 11.96 percent. This is a 17.02 percent decrease over earnings of $0.47 per share from the same period last year. The company reported quarterly sales of $5.427 billion which missed the analyst consensus estimate of $5.572 billion by 2.60 percent. This is a 1.23 percent increase over sales of $5.361 billion the same period last year.

Earnings Misses

Exelon Q2 Adj. EPS $0.39 Misses $0.44 Estimate, Sales $5.427B Miss $5.572B Estimate

Bombardier (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BBD#TSX">BBD</a>) reported quarterly earnings of $1.11 per share which beat the analyst consensus estimate of $1.09 by 1.83 percent. This is a 6.73 percent increase over earnings of $1.04 per share from the same period last year. The company reported quarterly sales of $2.028 billion which missed the analyst consensus estimate of $2.130 billion by 4.79 percent. This is a 7.94 percent decrease over sales of $2.203 billion the same period last year.

TSX:BBD

TSX:BBD.A

Bombardier Q2 Adj. EPS $1.11 Beats $1.09 Estimate, Sales $2.028B Miss $2.130B Estimate

KKR &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) reported quarterly earnings of $1.18 per share which beat the analyst consensus estimate of $1.16 by 2.08 percent. This is a 8.26 percent increase over earnings of $1.09 per share from the same period last year. The company reported quarterly sales of $1.857 billion which beat the analyst consensus estimate of $1.839 billion by 0.98 percent. This is a 7.47 percent increase over sales of $1.728 billion the same period last year.

KKR & Co Q2 Adj. EPS $1.18 Beats $1.16 Estimate, Sales $1.857B Beat $1.839B Estimate

CSW Industrials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSW#NYSE">CSW</a>) reported quarterly earnings of $2.85 per share which beat the analyst consensus estimate of $2.80 by 1.79 percent. This is a 15.38 percent increase over earnings of $2.47 per share from the same period last year. The company reported quarterly sales of $263.646 million which missed the analyst consensus estimate of $278.060 million by 5.18 percent. This is a 16.57 percent increase over sales of $226.177 million the same period last year.

CSW Industrials Q1 Adj. EPS $2.85 Beats $2.80 Estimate, Sales $263.646M Miss $278.060M Estimate

Kimco Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KIM#NYSE">KIM</a>) reported quarterly earnings of $0.44 per share which beat the analyst consensus estimate of $0.43 by 3.29 percent. This is a 7.32 percent increase over earnings of $0.41 per share from the same period last year. The company reported quarterly sales of $525.175 million which beat the analyst consensus estimate of $522.504 million by 0.51 percent. This is a 4.99 percent increase over sales of $500.231 million the same period last year.

Kimco Realty Q2 FFO $0.44 Beats $0.43 Estimate, Sales $525.175M Beat $522.504M Estimate

Needham analyst Chris Pierce maintains Carvana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) with a Buy and raises the price target from $340 to $500.

CVNA

Needham Maintains Buy on Carvana, Raises Price Target to $500

BIIB

Biogen shares are trading higher after the company reported better-than-expected Q2 results and raised its FY2025 adjusted EPS guidance above estimates.

Jefferies analyst Omar Nokta maintains Teekay Tankers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNK#NYSE">TNK</a>) with a Buy and maintains $55 price target.

Jefferies Maintains Buy on Teekay Tankers, Maintains $55 Price Target

Needham analyst Ryan Koontz maintains F5 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>) with a Buy and raises the price target from $320 to $345.

FFIV

Needham Maintains Buy on F5, Raises Price Target to $345

Ferrari (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RACE#NYSE">RACE</a>) reported quarterly earnings of $2.70 per share which beat the analyst consensus estimate of $2.39 by 13.08 percent. This is a 9.23 percent increase over earnings of $2.47 per share from the same period last year. The company reported quarterly sales of $2.03 billion which beat the analyst consensus estimate of $1.82 billion by 11.13 percent. This is a 9.93 percent increase over sales of $1.84 billion the same period last year.

RACE

Ferrari Q2 EPS $2.70 Beats $2.39 Estimate, Sales $2.03B Beat $1.82B Estimate

Press Releases

Perspective Therapeutics to Participate in Upcoming May Investor Conferences

Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results

Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting

Comments

Perspective Therapeutics

Actualités

Dernières nouvelles pour Perspective Therapeutics (AMEX:CATX) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL